Skip to main navigation Skip to search Skip to main content

A noncontrolled trial of anti-TNF-α chimeric monoclonal antibody (infliximab, Remicade(®)) in exudative age-related macular degeneration

  • P Martin van Hagen
  • , G Seerp Baarsma
  • , Christel E van Bilsen
  • , Robert W Kuijpers
  • , Jan A van Laar
  • , Marianne van der Ent
  • , Paul L van Daele
  • , Nico J Veeger
  • , Johannes R Vingerling
  • , Tom O Missotten

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)e691-2
JournalActa Ophthalmologica
Volume92
Issue number8
DOIs
Publication statusPublished - Dec 2014

Keywords

  • Administration, Topical
  • Aged
  • Anti-Inflammatory Agents, Non-Steroidal/adverse effects
  • Antibodies, Monoclonal/adverse effects
  • Contrast Sensitivity/drug effects
  • Exudates and Transudates
  • Humans
  • Infliximab
  • Ophthalmic Solutions
  • Tumor Necrosis Factor-alpha
  • Visual Acuity/drug effects
  • Wet Macular Degeneration/drug therapy

Cite this